Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) increased by 0.77% as of August 15, 2025, with notable gains from companies such as BeiGene (1.78%) and Innovent Biologics (1.67%) [3] - The Hong Kong Innovative Drug Selection ETF (520690) rose by 0.60%, marking its third consecutive increase, with the latest price at 1.01 yuan [3] - Over the past week, the Hong Kong Innovative Drug Selection ETF has accumulated a rise of 2.76% [3] Group 2 - According to Guojin Securities, China's innovative drugs are on the rise, entering the initial phase of realizing innovation results, with significant opportunities for independent development and large-scale transactions in BD authorization [4] - In the oncology sector, two main directions are highlighted: the multidimensional iteration of ADC (antibody-drug conjugates) and innovations in the molecular components of immunotherapy [4] - The latest scale of the Hong Kong Innovative Drug Selection ETF reached 396 million yuan, a new high since its establishment [4] Group 3 - The top ten weighted stocks in the HSSCPB index account for 77.96% of the index, including companies like BeiGene and WuXi Biologics [5] - The Hong Kong Innovative Drug Selection ETF closely tracks the HSSCPB index, which reflects the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [5]

Market Overview - Most large-cap stocks experienced declines, with HSBC Holdings closing at HKD 103.043, up 2.63% from the previous close, while Tencent Holdings closed at HKD 585.875, down 0.70% [1][2] Stock Performance Summary - Tencent Holdings (00700) latest price: HKD 590.000, change: +HKD 4.000 (+0.68%), ADR price: HKD 585.875, decline: -HKD 4.125 (-0.70%) [2] - Alibaba Group (09988) latest price: HKD 121.800, change: -HKD 1.900 (-1.54%), ADR price: HKD 119.737, decline: -HKD 2.063 (-1.69%) [2] - HSBC Holdings (00005) latest price: HKD 100.400, change: -HKD 0.315 (-0.31%), ADR price: HKD 103.043, increase: +HKD 2.643 (+2.63%) [2] - AIA Group (01299) latest price: HKD 76.900, change: +HKD 0.500 (+0.65%), ADR price: HKD 76.338, decline: -HKD 0.562 (-0.73%) [2] - Meituan (03690) latest price: HKD 124.400, change: +HKD 0.100 (+0.08%), ADR price: HKD 121.813, decline: -HKD 2.587 (-2.08%) [2] - NetEase (099999) latest price: HKD 207.800, change: -HKD 7.600 (-3.53%), ADR price: HKD 203.157, decline: -HKD 4.643 (-2.23%) [2] - Hong Kong Exchanges and Clearing (00388) latest price: HKD 439.200, change: -HKD 0.600 (-0.14%), ADR price: HKD 435.548, decline: -HKD 3.652 (-0.83%) [2] - Ping An Insurance (02318) latest price: HKD 57.900, change: +HKD 1.100 (+1.94%), ADR price: HKD 57.146, decline: -HKD 0.754 (-1.30%) [2] - JD.com (09618) latest price: HKD 125.100, change: -HKD 2.300 (-1.81%), ADR price: HKD 123.693, decline: -HKD 1.407 (-1.13%) [2] - Kuaishou Technology (01024) latest price: HKD 75.200, change: +HKD 0.250 (+0.33%), ADR price: HKD 74.811, decline: -HKD 0.389 (-0.52%) [2]

Core Insights - HHLR Advisors, a fund management platform under Hillhouse Capital, reported a total market value of $3.105 billion in its U.S. stock holdings as of the end of Q2 2025, with over 90% allocated to Chinese concept stocks, indicating a long-term bullish outlook on quality Chinese assets [1] Group 1: Holdings Overview - Eight out of the top ten holdings of HHLR are Chinese concept stocks, with Pinduoduo being the largest position, having increased by 20% year-to-date [1] - Futu Holdings has seen a remarkable year-to-date increase of 106%, reflecting strong performance among HHLR's key investments [1] - Other notable holdings include BeiGene, NetEase, Alibaba, and Legend Biotech, all of which have shown significant performance [1] Group 2: Recent Changes in Holdings - In Q2, HHLR increased its positions in Futu Holdings and Pinduoduo while partially reducing its stakes in Alibaba, Beike, and NetEase, which have experienced substantial price increases of 52% and 54% respectively year-to-date [1] - This adjustment in holdings suggests a strategy focused on locking in profits and optimizing asset allocation in a high market environment [1] Group 3: New Entrants - For the first time, Moomoo Securities entered HHLR's top ten holdings, with Hillhouse having participated in multiple financing rounds since 2021; Moomoo went public on NASDAQ in April this year, currently valued at approximately $7.5 billion [1]

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

Group 1 - The core index, the CESHKB, increased by 2.22% to 9684.5 points with a trading volume of 19.513 billion [1] - The CESHKB index has risen by 21.28% over the past month, 67.37% over the past three months, and 111.44% year-to-date [1] - The index is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, and a base point of 2000.0 [1] Group 2 - The top ten holdings of the CESHKB index include: - CanSino Biologics (13.85%) - Innovent Biologics (9.49%) - WuXi Biologics (8.72%) - 3SBio (8.71%) - BeiGene (8.39%) - WuXi AppTec (7.03%) - Kintor Pharmaceutical (5.02%) - Zai Lab (4.33%) - Nuo Therapeutics (3.91%) - Kingstar Biotech (3.8%) [1] - The CESHKB index is fully composed of companies listed on the Hong Kong Stock Exchange, with 100% of its holdings in the healthcare sector [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the Huatai Fuhua Medical Active Growth One-Year Holding Mixed Fund A, which has shown significant returns in various time frames [1] - As of June 30, 2025, the fund's total assets amount to 1.922 billion yuan, with a recent net value of 0.8263 yuan, reflecting a growth of 1.04% [1] - The fund has achieved a return of 15.15% over the past month, 63.14% over the past six months, and 66.59% year-to-date, ranking 506 out of 4688, 60 out of 4532, and 84 out of 4490 respectively in its category [1] Group 2 - The top ten stock holdings of the fund account for a total of 61.79%, with significant positions in companies such as Sanofi (10.07%), Innovent Biologics (8.94%), and Kelun-Biotech (8.71%) [1] - The fund was established on August 21, 2020, and is managed by Zheng Lei, who has extensive experience in the medical and healthcare investment sector [2]

Core Viewpoint - BeOne Medicines Ltd. has granted restricted stock units (RSUs) to 375 participants under the 2016 Option and Incentive Plan, totaling 34,361 American Depositary Shares (ADS), equivalent to 446,693 shares, representing approximately 0.03% of the company's total issued shares as of the announcement date [1]. Summary by Relevant Sections Grant Details - Grant Date: August 8, 2025 - Number of Participants: 375 - Total Number of RSUs Granted: 34,361 ADS - Total Number of Related Shares: 446,693 - Grant Price: $288.18 per ADS (approximately HKD 174.02 per ordinary share) [1]. Vesting Schedule - RSUs will vest 25% annually on the last trading day of each month for four years, contingent on the participants maintaining a service relationship with the company [1]. - For four non-senior management participants, RSUs will vest 25% annually on July 31 for four years, also contingent on continued employment [1]. Additional Information - The RSUs granted do not have performance targets and are considered competitive and in line with the company's practices [1]. - After this grant, there are still 59,660,288 shares available for future grants under the 2016 Option and Incentive Plan [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年8月8日， 董事會薪酬委員會根據2016期權及激勵計劃的條款向三百七十五名承授人授出涉 及合共34,361股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的受限制股份單位 受限制股份單位詳情如下： 1 授出日期： 2025年8月8日 承授人數目： 三百七十五名 已授出受限制股份單位涉及 的相關股份數目： 446,693 受限制股份單位總數（美國 存託股份）: 34,361 因已授出受限制股份單位獲 歸屬而可予獲得的新美國 存託股份總數： 34,361 授出的代價： 零 美國存託股份於授出日期 的收市價： 於2025年8月8日，董事會薪酬委員會根據2016期權及激勵計劃的條款授 ...

Core Viewpoint - BeiGene (06160.HK) announced the grant of a total of 34,361 restricted stock units to 375 grantees under the 2016 option and incentive plan, equivalent to 446,693 shares, representing approximately 0.03% of the company's total issued shares as of the announcement date [1] Summary by Category - **Company Actions** - The board's compensation committee granted restricted stock units to 375 individuals [1] - The total number of restricted stock units granted is 34,361 [1] - **Shareholder Impact** - The granted units correspond to 446,693 shares [1] - This represents about 0.03% of the total issued shares of the company as of the announcement date [1]

Core Viewpoint - The investment bank maintains a cautiously optimistic outlook on the Chinese pharmaceutical industry, noting a significant average increase of 137% in Hong Kong biotech stocks since early 2025, driven by cash returns from innovative drug licensing deals and unaffected by upcoming U.S. tariffs [1] Group 1: Market Performance - The biotech sector has recently experienced some pullback due to disappointing sales figures from major companies in the first half of 2025, including Hutchison China MediTech [1] - Concerns have arisen regarding Trump's phased implementation of drug tariffs, which could escalate to 150% within a year and ultimately reach 250% [1] Group 2: Company Recommendations - The bank's top pick is BeiGene (06160), with a target price set at HKD 230 and a rating of "Outperform," citing strong performance in the first half of 2025 and an improved gross margin guidance despite U.S. tariff impacts [1] - CanSino Biologics (09926) is expected to report adjusted earnings of RMB 23 million for the first half of 2025, benefiting from revenue growth from its drugs AK104 and AK112, also rated "Outperform" [1] - The target price for Innovent Biologics (01801) has been raised by 10% from HKD 100 to HKD 110, with a rating of "Outperform," reflecting confidence in the company's projected 37% year-on-year revenue growth [1] Group 3: Focus on Innovative Drugs - The bank continues to pay attention to licensing deals for Chinese innovative drugs, with expectations of increased subsidies for high-priced innovative drugs, which may drive sales growth for companies such as Kintor Pharmaceutical (02171), Fosun Pharma (02196), WuXi AppTec (02126), and Kelun-Biotech (06990) [2]